Want to see JBIO full AI Analyst Report?
JBIO Stock Chart & Stats
$21.84
$0.42(2.09%)
At close: 4:00 PM EDT
$21.84
$0.42(2.09%)
Day’s Range― - ―
52-Week Range$8.36 - $28.00
Previous CloseN/A
Volume1.06M
Average Volume (3M)904.31K
Market Cap
$875.74M
Enterprise Value$895.97M
Total Cash (Recent Filing)$461.20M
Total Debt (Recent Filing)$628.00K
Price to Earnings (P/E)―
Beta0.22
Next Earnings
Nov 16, 2026EPS Estimate
-0.73Next Dividend Ex-DateN/A
Dividend Yield23.67%
Share Statistics
EPS (TTM)-2.75
Shares Outstanding63,597,385
10 Day Avg. Volume797,007
30 Day Avg. Volume904,312
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.46
Price to Sales (P/S)0.00
P/FCF Ratio-5.10
Enterprise Value/Market Cap1.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-49.78K
Enterprise Value/Ebitda-5.73
Forecast
1Y Price Target
$50.50Price Target Upside131.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-2.95
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low Leverage And Strong CapitalizationExtremely low debt relative to equity gives Jade substantial financial flexibility while it advances its development programs. Strong capitalization can reduce balance-sheet pressure, support continued research investment, and provide greater resilience than a similarly unlevered development-stage biotech.
Differentiated JADE301 Development ProfileJADE301’s selective target binding, stronger comparator affinity, extended non-human-primate half-life, and favorable toxicology provide a credible basis for clinical advancement. If these attributes translate into humans, they could support differentiated efficacy, convenient dosing, and meaningful pipeline value.
Expanded Antibody Pipeline OptionalityThe worldwide exclusive license broadens Jade’s antibody pipeline and gives the company strategic control over a target without new Paragon campaigns for five years. This can expand future development opportunities and strengthen competitive positioning if the licensed assets validate clinically.
Bears Say
Pre-revenue Model With Widening LossesJade has no commercial revenue to absorb its operating costs, while losses have expanded materially from prior years. Until a candidate generates revenue, the company remains dependent on capital resources and successful clinical execution to establish a sustainable earnings base.
Accelerating Cash Burn And Funding DependenceThe worsening operating and free-cash-flow deficits indicate that Jade is consuming substantial cash while its programs remain in development. Persistent burn can increase reliance on future financing, constrain investment flexibility, and raise the consequences of delays or unfavorable clinical outcomes.
License Payments And Royalties May Burden Future EconomicsThe licensed assets carry meaningful milestone, sublicensing, and royalty obligations before and after any commercial success. These commitments could increase near-term cash requirements and reduce long-term margins or strategic flexibility if the programs advance and generate product revenue.
Jade Biosciences News
JBIO FAQ
What was Jade Biosciences’s price range in the past 12 months?
Jade Biosciences lowest stock price was $8.36 and its highest was $28.00 in the past 12 months.
What is Jade Biosciences’s market cap?
Jade Biosciences’s market cap is $875.74M.
When is Jade Biosciences’s upcoming earnings report date?
Jade Biosciences’s upcoming earnings report date is Nov 16, 2026 which is in 37 days.
How were Jade Biosciences’s earnings last quarter?
Jade Biosciences released its earnings results on Aug 10, 2026. The company reported -$0.76 earnings per share for the quarter, missing the consensus estimate of -$0.636 by -$0.124.
Is Jade Biosciences overvalued?
According to Wall Street analysts Jade Biosciences’s price is currently Undervalued.
Does Jade Biosciences pay dividends?
Jade Biosciences pays a Notavailable dividend of $2.4 which represents an annual dividend yield of 23.67%. See more information on Jade Biosciences dividends here
What is Jade Biosciences’s EPS estimate?
Jade Biosciences’s EPS estimate is -0.73.
How many shares outstanding does Jade Biosciences have?
Jade Biosciences has 63,597,385 shares outstanding.
What happened to Jade Biosciences’s price movement after its last earnings report?
Jade Biosciences reported an EPS of -$0.76 in its last earnings report, missing expectations of -$0.636. Following the earnings report the stock price went down -1.047%.
Which hedge fund is a major shareholder of Jade Biosciences?
Currently, no hedge funds are holding shares in JBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jade Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.50 (131.23% Upside)
$50.50 (131.23% Upside)
Blogger Sentiment
Bullish
JBIO Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 5.0%
Last 30 Days ▼ 5.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
55.83%
12-Months-Change
Fundamentals
Return on Equity
-49.11%
Trailing 12-Months
Asset Growth
110.79%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Jade Biosciences
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
JBIO Stock 12 Month Forecast
Average Price Target
$50.50
▲(131.23% Upside)
Technical Analysis
Ownership Overview
8.01% Insiders
13.47% Mutual Funds
54.80% Other Institutional Investors
12.67% Public Companies and
Individual Investors